Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients

Incannex Healthcare Limited (NASDAQ:IXHL) has completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA).

  • The clinical trial assessed three doses of IHL-42X at reducing the apnoea hypopnoea index (AHI), the main diagnostic and monitoring criteria for OSA, compared to placebo. 
  • For all IHL-42X treatment periods (using low, mid, and high doses), the average AHI was 23.81, a 44.4 % reduction from the baseline score of 42.84, compared to a 6.4% reduction in the placebo group.
  • Related: Medicinal Cannabis And Psychedelics Company Incannex Lists American Depositary Shares On Nasdaq
  • 60% of participants experienced a reduction in AHI of over 50% (55.0% to 91.5%) and a resulting AHI of less than 20 during at least one treatment period of one dose strength of IHL-42X. 
  • 20% of participants experienced a reduction in AHI of over 80% (82.7% to 91.5%) relative to baseline.
  • Incannex is preparing for a pre-IND meeting with the FDA on the future development plan for IHL-42X, scheduled on May 11.
  • The meeting will guide what data is required to open an Investigational New Drug (IND) application for a larger pivotal phase 2 trial.
  • Price Action: IXHL shares closed at $10.46 on Tuesday before trading halt.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.